ClearB Therapeutics Announces Sentinel Safety Outcome and Opening of the Remainder of the Cohort in a Phase 1b First in Human Study of CLB-4000 for the Treatment of Chronic Hepatitis B Infection
ClearB Therapeutics Announces Sentinel Safety Outcome and Opening of the Remainder of the Cohort in a Phase 1b First in Human Study of CLB-4000 for the Treatment of Chronic Hepatitis B Infection. NEWTON, MA, October 15, 2025 – ClearB Therapeutics, Inc., a clinical-stage biotechnology company committed [...]